The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia

This qualitative study seeks to explore the unmet needs of individuals who have recently undergone a cancer diagnosis and completed the acute phase of treatment. The primary objective is to utilize the experiences of patients, caregivers, and stakeholders to enhance the aftercare provided to cancer survivors. By delving into patient perceptions regarding unmet needs in cancer aftercare, the study aims to identify areas for redesigning and improving services to minimize these needs and ultimately enhance patient outcomes. Importantly, the investigation incorporates insights from patients, their caregivers, and stakeholders. The research will employ qualitative methods, specifically focus groups and interviews, to gather comprehensive perspectives from individuals in the Ausl IRCCS Reggio Emilia district who have completed treatment for breast, prostate, colorectal, thyroid, and multiple myeloma cancers. Including patients with diverse cancer types is crucial for capturing a broad spectrum of experiences. During data collection, both focus group discussions and interviews will be recorded in audio format and transcribed verbatim. This meticulous approach ensures an accurate representation of participants' voices and experiences. The subsequent analysis will employ a combination of framework and thematic analysis to extract meaningful insights and synthesize the data effectively. The study's ultimate goal is to leverage the findings to optimize aftercare services for cancer survivors within the local context of Ausl IRCCS Reggio Emilia. By incorporating the perspectives of patients, caregivers, and stakeholders, the research aims to contribute valuable insights that can inform the redesign and improvement of aftercare services, ultimately benefitting cancer survivors in the region.

NCT Number	NCT06236373
Lead Sponsor	University of Modena and Reggio Emilia Collaborators: Azienda USL - IRCCS di Reggio Emilia
Conditions	Cancer, Breast Cancer, Prostate Cancer, Thyroid Cancer, Colorectal Cancer, Lymphoma, Multiple Myeloma, Neoplasms
Enrollment	45 participants
Start Date	2023-04-20
Primary Completion	2025-02 (estimated)
Study Completion	2025-10 (estimated)
Updated on ClinicalTrials.gov	2024-12-09